Thursday, February 26, 2015 Last update: 3:03 PM
FreshNews.com - Covering Large & Obscure Tech Companies Since 1996

Regulus Therapeutics Inc.

News articles for Regulus Therapeutics Inc.:

Thursday, February 26, 2015

  • Regulus to Present at Cowen and Company 35th Annual Healthcare Conference
    LA JOLLA, Calif., Feb. 26, 2015 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Kleanthis G. Xanthopoulos, Ph.D., President and Chief Executive Officer of Regulus, will present a company overview at the Cowen ... read more

Thursday, February 19, 2015

  • Regulus to Present at 2015 RBC Capital Markets' Healthcare Conference
    LA JOLLA, Calif., Feb. 19, 2015 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Paul Grint, M.D., Chief Medical Officer of Regulus, will present a company overview at the 2015 RBC Capital ... read more

Wednesday, February 18, 2015

  • Regulus Reports Fourth Quarter and Year-End 2014 Financial Results and Recent Highlights
    LA JOLLA, Calif., Feb. 18, 2015 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported financial results for the fourth quarter and year ended December 31, 2014, including a summary of recent corporate highlights. http://photos.prnewswire.com/prnvar/20150130/172637LOGO "In 2014 and the ... read more

Thursday, February 12, 2015

Monday, February 9, 2015

Monday, February 2, 2015

Thursday, January 8, 2015

  • Regulus Announces Key Goals Under its 'Clinical Map Initiative' for 2015
    LA JOLLA, Calif., Jan. 8, 2015 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced key goals for 2015 under its 'Clinical Map Initiative' to advance its microRNA therapeutics portfolio and biomarkers platform. "Regulus enters 2015 with the scientific ... read more

Wednesday, November 26, 2014

Saturday, November 15, 2014

Thursday, November 6, 2014

  • Regulus to Present at the Credit Suisse Healthcare Conference
    LA JOLLA, Calif., Nov. 6, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Kleanthis G. Xanthopoulos, Ph.D., President and CEO of Regulus, will present a company overview at the Credit Suisse Healthcare ... read more

Wednesday, November 5, 2014

  • Regulus Reports Third Quarter 2014 Financial Results and Recent Highlights
    LA JOLLA, Calif., Nov. 5, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported financial results and highlights for the quarter ended September 30, 2014 and provided a summary of recent corporate highlights. "The third quarter and recent ... read more

Monday, November 3, 2014

Thursday, October 30, 2014

Tuesday, October 28, 2014

  • Regulus Announces Pricing of Public Offering of Common Stock
    LA JOLLA, Calif., Oct. 28, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company developing innovative medicines targeting microRNAs, today announced the pricing of an underwritten public offering of 5,294,118 shares of its common stock at a price to the public of $17.00 per share. ... read more

Monday, October 27, 2014

  • Regulus Announces Commencement of Public Offering of Common Stock
    LA JOLLA, Calif., Oct. 27, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company developing innovative medicines targeting microRNAs, today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell approximately $80,000,000 of shares of its ... read more

Wednesday, October 22, 2014

Tuesday, October 14, 2014

Wednesday, September 24, 2014

Thursday, September 18, 2014